Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2017-07-17 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
关于对外投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding an external investment in a new company, Hebei Antu Langjian Medical Technology Co., Ltd. It details the investment amount, shareholding structure, cooperation agreement, governance, performance commitments, and risk warnings. The document is a formal disclosure of a capital investment transaction and related agreements. It does not contain financial statements, audit opinions, earnings results, or management discussion of financial performance. It is not a report but an announcement of a financing/investment activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about the investment transaction, supporting a high confidence classification as CAP.
2017-07-17 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle funds. It details the company's purchase and management of various financial products, including open-ended wealth management products and other financial products, with specific dates and amounts. The document is relatively short (2051 characters) and focuses on updates about financing activities related to the company's cash management and investment of idle funds. There is no indication that this is a full financial report, audit, or earnings release. It is not a regulatory certification or a report publication announcement. The content fits best with a Capital/Financing Update (CAP) as it provides updates on the company's financing activities and capital management.
2017-07-03 Chinese
关于收购百奥泰康75%股权并对其增资完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the acquisition of 75% equity in another company (Beijing Bai'ao Taikang Biotechnology Co., Ltd.) and completion of related registration changes. It details the board meeting approval, signing of agreements, and completion of business registration changes. The content focuses on a corporate transaction and capital increase, not on financial results, audit, or regulatory certifications. The document length is short (895 characters) and it is a formal announcement of a corporate action related to capital and ownership changes. Therefore, it fits best under Capital/Financing Update (CAP).
2017-07-03 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the company's use of idle raised funds for cash management, detailing purchases and redemptions of financial products. It includes specific dates, amounts, and yields related to entrusted financial products. The document is relatively short (1398 characters) and is an update on financing activities rather than a full financial report or audit. It does not contain comprehensive financial statements or management analysis but focuses on capital management activities. Therefore, it fits best under Capital/Financing Update (CAP).
2017-07-03 Chinese
关于全资子公司完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of business registration changes for a wholly-owned subsidiary, including changes in legal representative, address, and business scope. It is a formal disclosure by the board but does not contain financial data, audit information, or details of management changes at the parent company level. It is not a report, earnings release, or regulatory filing related to financial performance or governance changes. The content fits best under general regulatory announcements about corporate administrative changes, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2017-06-12 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle funds, detailing purchases and redemptions of financial products with banks. It includes specific transaction dates, amounts, and yields but does not contain comprehensive financial statements or analysis typical of financial reports. The document length is 2220 characters, which is relatively short and focused on a specific financing activity update. It is not an annual or interim report, earnings release, or audit report. It is an update on the company's capital management activities, specifically about entrusted financial products and cash management progress. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2017-06-07 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.